No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
592 |
4. Check minimum number of eventsNone |
592 |
5. Include endpointsNone |
592 |
6. Filter based on genotype QC (FinnGen only) |
530 |
Control definitions (FinnGen only)
- Control exclude
- H7_EYEOTH
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- H55-H59
- Name in latin
- Nystagmus et alii motus irregulares oculi
Similar endpoints
↥List of similar endpoints to
Nystagmus and other irregular eye movements
based on the number of shared cases.
Similar with more cases:
- Other disorders of eye and adnexa
- Diseases of the eye and adnexa
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4714 | 2279 | 2421 |
| Only index persons | 3952 | 1959 | 1993 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.07 | 0.07 |
| Only index persons | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 25.97 | 30.97 | 21.18 |
| Only index persons | 32.97 | 36.00 | 30.00 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 530 | 318 | 212 |
| Unadjusted period prevalence (%) | 0.11 | 0.11 | 0.10 |
| Median age at first event (years) | 46.71 | 44.47 | 50.07 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 557
- Matched controls
- 5568
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
4503599627370496.0
307.7
545
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.3
70.0
142
289
R42
ICD-10 Finland
Dizziness and giddiness
4.6
64.9
219
683
G35
ICD-10 Finland
Multiple sclerosis
16.6
61.3
53
35
H53.2
ICD-10 Finland
Diplopia
11.1
60.7
68
69
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.4
58.9
140
326
109
Kela drug reimbursment
Multiple sclerosis
16.1
48.1
42
28
AA1AD
NOMESCO Finland
CT of head and brain
3.6
46.2
229
902
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
16.0
41.1
36
24
XCK00
NOMESCO Finland
Perimetry
6.3
41.0
75
135
H50.0
ICD-10 Finland
Convergent concomitant strabismus
14.4
36.8
34
25
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
15.2
36.8
33
23
H81.2
ICD-10 Finland
Vestibular neuronitis
11.0
35.5
39
38
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.2
33.1
99
270
N29
ICPC
Neurological sympt/complt other
11.2
32.5
35
33
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.2
32.4
165
641
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.1
31.8
37
39
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.0
30.7
49
76
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.1
29.0
65
140
XA800
NOMESCO Finland
Neuropsychological investigation
5.0
28.1
65
144
N03AF02
ATC
oxcarbazepine; oral
6.1
27.4
50
89
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.4
26.8
111
376
G40.9
ICD-10 Finland
Epilepsy, unspecified
6.2
26.8
48
84
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
31.0
26.6
35
12
Z3229
NOMESCO Finland
Other healthcare associate professional
4.1
26.4
81
224
N03AX14
ATC
levetiracetam; systemic
7.2
26.2
40
59
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.1
25.5
78
215
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
7.6
24.9
36
50
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.7
23.7
83
251
3795A
ICD-9 Finland
Other disorders of eye, Nystagmus and other irregular eye movements
+∞
22.0
21
*
H47.2
ICD-10 Finland
Optic atrophy
43.4
20.6
25
6
M03BX01
ATC
baclofen; systemic
7.2
20.6
31
45
L28
ICPC
Limited function/disability (L)
2.8
20.0
123
517
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.8
19.4
111
449
N03AX09
ATC
lamotrigine; oral
4.0
19.0
57
154
N03AE01
ATC
clonazepam; systemic
4.1
18.3
52
135
SPAT1229
SPAT
Assessment of need for aid
4.0
18.1
55
150
TAB00
NOMESCO Finland
Lumbar puncture
4.1
17.8
52
138
Z2446
NOMESCO Finland
Social worker
3.2
17.8
76
260
H52.1
ICD-10 Finland
Myopia
4.2
17.5
48
121
H53.0
ICD-10 Finland
Amblyopia ex anopsia
7.6
17.5
25
34
R27.0
ICD-10 Finland
Ataxia, unspecified
32.6
17.1
22
7
Z2445
NOMESCO Finland
Psychologist
3.7
17.1
58
171
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.8
16.8
54
153
R1250
NOMESCO Finland
Evaluation of functional capability
5.8
15.2
28
50
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.6
15.2
37
85
H52.2
ICD-10 Finland
Astigmatism
5.0
15.1
33
69
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
14.7
168
923
H50.30
ICD-10 Finland
Intermittent esotropy
14.7
14.7
24
17
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
4.9
14.6
33
71
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
153.8
14.5
15
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.0
14.4
67
240
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.5
14.2
101
452
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
6.2
14.0
24
40
N86
ICPC
Multiple sclerosis
18.1
13.9
21
12
H50.1
ICD-10 Finland
Divergent concomitant strabismus
17.2
13.1
20
12
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
6.3
13.0
22
36
N18
ICPC
Paralysis/weakness
6.3
13.0
22
36
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
13.4
13.0
22
17
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
2.8
13.0
68
260
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
6.0
12.8
23
40
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
12.7
136
722
164
Kela drug reimbursment
Fingolimod
32.9
12.6
16
5
A28
ICPC
Limited function/disability NOS
2.4
12.3
98
460
N03AX18
ATC
lacosamide; systemic
16.3
12.2
19
12
N17
ICPC
Vertigo/dizziness
2.5
12.1
87
389
N28
ICPC
Limited function/disability (N)
9.0
12.1
25
29
L03AB07
ATC
interferon beta-1a; parenteral
13.8
12.0
20
15
N03AX12
ATC
[U] gabapentin; oral
2.3
11.8
101
488
H53.1
ICD-10 Finland
Subjective visual disturbances
3.0
11.8
56
203
H27.0
ICD-10 Finland
Aphakia
30.7
11.7
15
5
H57.1
ICD-10 Finland
Ocular pain
4.0
11.5
33
86
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.1
11.5
50
172
N05BA09
ATC
clobazam; oral
12.2
11.4
20
17
L03AX13
ATC
glatiramer acetate; parenteral
15.4
11.4
18
12
R4130
NOMESCO Finland
Speech therapy
4.0
11.3
32
83
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
11.2
257
1763
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.2
11.1
45
148
N99
ICPC
Neurological disease other
9.5
11.1
22
24
H52.0
ICD-10 Finland
Hypermetropia
4.3
11.0
29
71
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.7
10.9
64
259
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
10.9
82
374
N03AG01
ATC
valproic acid; systemic, rectal
3.0
10.8
50
178
Q12.0
ICD-10 Finland
Congenital cataract
28.6
10.8
14
5
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
5.6
10.5
20
37
E70.3
ICD-10 Finland
Albinism
+∞
10.4
10
*
78112
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Nystagmus
+∞
10.4
10
*
4AA23, ,
NOMESCO Finland
+∞
10.4
10
*
R4120
NOMESCO Finland
Occupational therapy
2.8
10.3
55
212
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.6
10.3
65
273
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
13.4
10.2
17
13
SPAT1216
SPAT
Assessment of functional ability
2.3
10.1
82
387
G91.1
ICD-10 Finland
Obstructive hydrocephalus
14.9
10.0
16
11
L04AA27
ATC
[U] fingolimod
40.8
10.0
12
*
L04AA31
ATC
[U] teriflunomide
40.8
10.0
12
*
F83
ICD-10 Finland
Mixed specific developmental disorders
5.3
9.9
20
39
R5110, ,
SPAT
2.7
9.9
55
217
353
Kela drug reimbursment
Cladribine and fingolimod
26.5
9.8
13
5
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
9.8
138
803
H54.7
ICD-10 Finland
Unspecified visual loss
13.7
9.7
16
12
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
11.6
9.6
17
15
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.3
9.6
79
375
XF400
NOMESCO Finland
ECG with 12 standard connections
2.1
9.5
97
501
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
4.2
9.5
25
61
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.7
9.5
55
221
DFF59
NOMESCO Finland
Other assessment of balance
12.6
9.4
16
13
N04BB01
ATC
amantadine; oral
9.7
9.3
18
19
R13
ICD-10 Finland
Dysphagia
2.7
9.3
50
194
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.5
9.2
22
50
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.1
9.1
97
509
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
2.9
9.1
44
161
A06AD11
ATC
lactulose; oral
2.3
9.1
72
336
R4110
NOMESCO Finland
Physiotherapy
1.8
9.0
166
1052
N03AX11
ATC
topiramate; oral
3.9
8.9
26
69
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
8.6
151
941
N05CD08
ATC
midazolam; nasal, systemic
4.3
8.5
22
53
H50.8
ICD-10 Finland
Other specified strabismus
28.0
8.5
11
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.3
8.5
67
312
R1260
NOMESCO Finland
Evaluation of communicative skills
5.0
8.4
18
37
RS221, ,
NOMESCO Finland
4.8
8.4
19
41
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.1
8.3
92
489
183
Kela drug reimbursment
Lamotrigin and topiramate
7.2
8.3
19
27
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.5
8.2
20
46
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
8.2
167
1085
Z3226
NOMESCO Finland
Physiotherapist
1.9
8.2
115
666
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
2.8
8.1
42
160
AA7AA
NOMESCO Finland
Liquor cerebri shunt X-ray examinatin without contrast
22.4
8.0
11
5
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
3.7
7.9
25
70
Z31.5
ICD-10 Finland
Genetic counselling
2.5
7.9
50
210
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.3
7.9
62
288
H46
ICD-10 Finland
Optic neuritis
8.6
7.9
16
19
H50.2
ICD-10 Finland
Vertical strabismus
8.6
7.9
16
19
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.3
7.8
59
269
Z3231
NOMESCO Finland
Registered nurse
1.8
7.8
163
1064
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.0
7.8
87
464
ZXA10
NOMESCO Finland
Bilateral
1.9
7.8
104
591
H53.9
ICD-10 Finland
Visual disturbance, unspecified
3.3
7.8
29
91
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
15.3
7.7
12
8
CE2W4
NOMESCO Finland
Eye movement mapping
45.6
7.7
9
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
8.2
7.6
16
20
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.3
7.6
59
272
G81.9
ICD-10 Finland
Hemiplegia, unspecified
9.0
7.6
15
17
R56.8
ICD-10 Finland
Other and unspecified convulsions
2.7
7.5
41
160
R51.80
ICD-10 Finland
Headache
1.9
7.5
107
622
UKC02
NOMESCO Finland
Cystoscopy
2.1
7.4
74
378
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
81.1
7.4
8
*
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
81.1
7.4
8
*
P85
ICPC
Mental retardation
13.6
7.4
12
9
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.2
7.4
29
94
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
7.0
7.3
17
25
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
11.1
7.3
13
12
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
9.5
7.3
14
15
H53.5
ICD-10 Finland
Colour vision deficiencies
+∞
7.3
7
*
G11.2
ICD-10 Finland
Late-onset cerebellar ataxia
+∞
7.3
7
*
N06AX11
ATC
mirtazapine; oral
1.7
7.3
184
1262
H81.4
ICD-10 Finland
Vertigo of central origin
16.0
7.2
11
7
DFF00
NOMESCO Finland
Pure tone audiometry
2.3
7.2
58
272
R3120
NOMESCO Finland
Training in mobility skills
20.3
7.2
10
5
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
4.1
7.1
19
47
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.0
7.1
84
458
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
10.2
7.1
13
13
S06.0
ICD-10 Finland
Concussion
2.0
6.9
73
382
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.6
6.9
208
1490
CS494
NOMESCO Finland
Other visual field testing
3.9
6.9
20
53
37300
ICD-8 Finland
Strabismus, Concomitans convergens
9.5
6.8
13
14
74439
ICD-8 Finland
Congenital anomalies of eye, Cataracta NUD
40.5
6.8
8
*
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
40.5
6.8
8
*
ZXA05
NOMESCO Finland
Left side
1.8
6.7
117
722
205
Kela drug reimbursment
Chronic hypertension
1.8
6.7
106
635
K02.1
ICD-10 Finland
Caries of dentine
1.6
6.7
345
2801
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.7
6.6
146
961
Z01.1
ICD-10 Finland
Examination of ears and hearing
1.9
6.6
83
461
WX110
NOMESCO Finland
Infiltration anesthesia
1.7
6.6
407
3448
R47.1
ICD-10 Finland
Dysarthria and anarthria
10.2
6.6
12
12
WX002
NOMESCO Finland
Sedation and analgesia
1.8
6.6
99
584
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
7.0
6.5
15
22
N07CA01
ATC
betahistine; oral
2.5
6.5
40
166
N02BF01
ATC
gabapentin; oral
2.1
6.5
60
298
SPAT1301
SPAT
No procedures
1.7
6.4
164
1121
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
7.5
6.4
14
19
7433A
ICD-9 Finland
Congenital anomalies of eye, Congenital cataract and lens anomalies
70.6
6.4
7
*
SPAT1234
SPAT
Support of social functional capacity
3.0
6.4
28
97
XCK10
NOMESCO Finland
Photography of fundus of eye
2.3
6.4
50
232
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
2.3
6.4
46
206
ZXA00
NOMESCO Finland
Right side
1.7
6.4
130
838
WX140
NOMESCO Finland
Parabulbar anesthesy
2.9
6.4
29
103
SFA10
NOMESCO Finland
One-surface restoration
1.6
6.3
313
2502
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
11.2
6.3
11
10
ZX120
NOMESCO Finland
Intravenous
2.2
6.3
56
274
G44.2
ICD-10 Finland
Tension-type headache
1.9
6.3
83
469
N05AH04
ATC
quetiapine; oral
1.8
6.3
110
679
7423A
ICD-9 Finland
Other congenital anomalies of nervous system, Congenital hydrocephalus
+∞
6.3
6
*
G04BD09
ATC
trospium; oral
5.1
6.2
18
36
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.7
6.2
132
859
H53.4
ICD-10 Finland
Visual field defects
4.0
6.2
17
43
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
6.4
6.2
15
24
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
5.4
6.2
17
32
H81.9
ICD-10 Finland
Disorder of vestibular function, unspecified
7.8
6.1
13
17
ZXE10
NOMESCO Finland
More than one and less than three hours
1.6
6.1
183
1300
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.5
6.1
20
58
-45
ICPC
Observ/health educat/advice/diet
3.5
6.1
20
58
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
6.1
6.0
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
257
1341
2.70
28.64
2.9
2.1
189.70
241.04
u/l
0.34
247
1272
28
36
8.13
20.57
1.1
1.0
—
—
—
0
0
49
121
4.34
18.40
1.9
2.3
15.78
12.67
e6/l
0.12
32
86
49
122
4.31
18.21
1.9
2.3
178.18
133.43
e6/l
0.10
34
91
32
55
6.11
18.09
2.7
1.4
—
—
—
0
0
341
2335
2.19
17.49
10.7
8.8
1.22
1.21
mmol/l
0.42
301
2039
30
53
5.92
16.49
1.1
1.1
—
—
—
0
0
30
55
5.71
15.87
1.1
1.1
—
—
—
0
0
296
1989
2.04
15.12
5.9
5.7
35.96
36.36
g/l
0.59
268
1880
311
2128
2.04
15.09
10.0
8.8
1.22
1.22
mmol/l
0.10
290
1978
25
25
10.41
13.10
1.1
1.3
132.00
143.46
nmol/l
0.44
25
25
17
6
29.14
13.02
3.6
1.2
—
—
—
0
0
36
92
4.11
12.91
1.2
1.2
—
—
—
0
0
280
1948
1.88
11.91
14.8
10.6
1.18
1.18
inr
0.01
233
1598
109
557
2.19
11.11
1.9
2.3
360.06
379.44
nmol/l
0.47
101
531
22
25
9.11
10.85
2.3
1.3
—
—
—
0
0
24
51
4.87
10.80
1.0
1.1
—
—
—
0
0
329
2457
1.83
10.70
7.3
6.9
12.74
13.27
umol/l
0.15
310
2342
454
3778
2.09
10.39
4.5
4.3
14.81
14.64
pmol/l
0.71
421
3510
359
2781
1.82
10.06
7.3
6.3
6.40
6.53
mmol/l
0.67
342
2609
73
330
2.39
9.88
2.5
2.9
65.40
66.97
g/l
0.84
68
313
71
322
2.38
9.54
1.5
1.3
71.00
32.44
au/ml
—
6
20
367
2898
1.78
9.24
11.8
10.5
4.13
4.01
e9/l
0.30
318
2506
196
1298
1.79
9.17
1.9
1.6
19.95
21.05
nmol/l
0.44
176
1105
21
30
7.23
9.10
1.1
1.0
1.47
1.13
u/l
0.27
11
14
13
7
18.96
8.96
1.1
2.0
—
—
—
0
0
201
1356
1.75
8.74
4.5
3.2
0.56
0.37
e6/l
0.26
156
969
208
1428
1.73
8.44
3.0
2.6
54.35
62.69
u/l
1.05
189
1333
73
356
2.21
8.26
2.7
2.4
11.00
20.15
au/ml
—
8
28
233
1681
1.66
7.68
4.1
3.5
29.48
31.90
u/l
0.68
220
1596
220
1566
1.67
7.62
4.6
3.4
31.21
92.73
e6/l
0.77
177
1172
19
32
6.11
7.43
1.1
1.1
—
—
—
0
0
497
4422
2.15
7.41
5.9
5.3
1.87
1.88
mu/l
0.03
469
4144
161
1062
1.73
7.37
3.1
2.8
4.19
6.14
e6/l
1.22
149
961
14
15
9.54
7.32
1.1
1.1
—
—
—
0
0
14
15
9.54
7.32
1.1
1.1
—
—
—
0
0
114
682
1.84
7.26
9.9
8.2
1.09
1.12
mmol/l
0.35
106
643
124
762
1.81
7.23
2.1
2.0
—
—
—
0
0
419
3546
1.73
7.15
9.5
8.0
82.89
82.64
u/l
0.03
402
3367
19
34
5.74
7.12
1.1
1.2
0.59
0.54
ratio
0.30
11
17
218
1574
1.63
7.00
3.7
3.3
2.37
2.36
mmol/l
0.84
195
1440
281
2165
1.60
6.86
3.5
2.8
80.44
75.00
nmol/l
2.13
260
1993
106
633
1.83
6.76
6.7
9.8
104.38
104.36
mmol/l
0.01
106
633
109
658
1.82
6.71
2.0
1.7
959.10
1186.47
nmol/l
2.13
82
508
54
255
2.24
6.60
1.9
1.7
—
—
—
0
0
13
15
8.84
6.58
1.2
1.3
—
—
—
0
0
519
4753
2.34
6.28
24.8
16.7
139.56
139.65
mmol/l
0.37
512
4662
519
4760
2.32
6.13
25.1
16.9
3.94
3.96
mmol/l
0.60
509
4655
484
4343
1.87
5.89
5.2
4.7
5.81
5.83
mmol/l
0.17
449
4029
97
587
1.79
5.89
1.9
1.9
—
—
—
0
0
12
15
8.15
5.86
1.3
1.2
—
—
—
0
0
10
9
11.28
5.81
1.2
1.4
—
—
—
0
0
20
60
3.42
5.77
1.5
1.9
—
—
—
0
0
51
251
2.14
5.65
4.7
7.5
0.60
0.62
%
0.11
51
251
179
1290
1.57
5.53
2.4
2.3
3.19
2.76
mg/l
0.74
155
1128
34
143
2.47
5.41
2.1
2.0
206.72
352.97
ug/l
0.90
34
133
15
30
5.11
5.28
1.2
1.1
1872.00
1717.50
miu/ml
0.17
15
30
11
15
7.45
5.16
1.2
1.1
—
—
—
0
0
8
6
13.50
5.09
1.3
1.7
—
—
—
0
0
21
71
3.03
5.03
1.5
1.8
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
15
32
4.79
5.02
1.1
1.2
—
—
—
0
0
406
3537
1.54
4.88
4.7
4.4
9.82
10.58
mm/h
0.74
379
3305
25
97
2.65
4.70
1.4
1.3
—
—
—
0
0
25
97
2.65
4.70
1.4
1.3
—
—
—
0
0
122
832
1.60
4.69
4.3
2.9
1.11
0.82
e6/l
0.29
65
417
7
5
14.15
4.58
1.1
1.2
—
—
—
0
0
245
1947
1.46
4.55
2.6
2.0
96.59
97.43
pmol/l
0.10
156
1020
313
2607
1.46
4.53
5.6
3.8
0.00
3.00
estimate
0.50
73
542
385
3339
1.49
4.52
4.4
3.5
45.29
43.72
u/l
0.14
362
3176
63
363
1.83
4.48
7.2
5.2
100.33
76.96
ng/l
1.10
55
331
88
561
1.67
4.41
2.0
1.9
—
—
—
0
0
115
784
1.59
4.41
4.6
3.0
1.84
2.13
e6/l
0.23
58
371
116
795
1.58
4.34
3.3
2.6
13.05
13.58
umol/l
0.33
107
748
7
6
11.79
4.28
1.3
1.5
—
—
—
0
0
7
6
11.79
4.28
1.1
1.5
—
—
—
0
0
160
1183
1.49
4.22
3.2
2.4
—
—
—
0
0
125
877
1.55
4.22
1.7
1.7
463.01
440.34
pmol/l
0.45
105
749
12
25
4.88
4.20
1.1
1.2
—
—
—
0
0
167
1248
1.48
4.18
1.7
1.5
2.12
2.21
g/l
0.31
115
755
312
2623
1.43
4.14
5.6
3.8
0.00
0.60
estimate
0.52
65
514
122
856
1.54
4.11
2.7
2.6
2.47
2.44
mmol/l
1.67
103
772
201
1564
1.45
4.06
3.8
3.6
7.21
8.00
mmol/l
1.56
181
1344
512
4787
1.86
3.93
21.9
14.5
21.93
22.32
mg/l
0.09
430
3834
306
2580
1.41
3.90
5.5
3.8
0.00
0.00
estimate
0.50
73
542
76
483
1.66
3.85
8.7
11.6
0.81
0.87
mmol/l
0.04
65
407
7
8
8.84
3.78
1.3
1.4
—
—
—
0
0
161
1216
1.46
3.76
3.1
3.7
1049.88
1092.16
ng/l
0.06
141
1031
31
148
2.16
3.76
2.1
1.7
—
—
—
0
0
269
2231
1.40
3.70
3.3
2.8
—
—
estimate
—
0
0
57
340
1.75
3.64
4.9
3.8
1.23
1.23
mmol/l
0.27
45
290
119
852
1.50
3.62
4.3
3.9
208.56
534.32
ng/l
1.00
91
594
11
26
4.29
3.52
1.1
1.1
—
—
—
0
0
526
4984
1.99
3.52
15.3
11.5
26.47
26.46
u/l
0.00
514
4867
73
471
1.63
3.49
6.6
6.4
—
—
—
0
0
15
52
2.94
3.48
2.5
3.5
—
—
—
0
0
471
4338
1.55
3.48
18.5
13.4
87.70
86.21
ml/min/173m2
0.72
435
3942
27
128
2.17
3.35
3.1
3.0
1.88
2.45
index
0.16
16
71
202
1618
1.39
3.33
3.9
3.4
33.98
30.41
ng/l
0.11
150
1057
106
755
1.50
3.30
3.2
2.6
2.37
2.37
g/l
0.02
97
703
174
1361
1.40
3.30
4.4
4.2
8.40
8.07
mg/mmol
0.04
115
868
24
110
2.23
3.23
6.2
4.2
1.36
2.69
ratio
1.05
16
62
98
691
1.51
3.20
3.3
2.6
20.82
23.03
%
1.17
92
654
8
16
5.05
3.06
1.1
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
25
122
2.10
2.91
3.4
9.5
0.52
0.37
iu/ml
0.51
12
63
34
186
1.88
2.90
2.0
1.6
1.23
1.17
g/l
0.58
34
180
5
6
8.39
2.75
1.2
1.0
—
—
—
0
0
5
6
8.39
2.75
1.2
1.0
—
—
—
0
0
483
4533
1.49
2.63
5.2
4.8
4.54
4.66
mmol/l
1.69
451
4268
288
2499
1.31
2.62
3.7
3.2
149.92
98.59
ug/l
0.92
274
2361
29
156
1.91
2.61
2.2
1.8
—
—
—
0
0
16
68
2.39
2.57
1.7
1.3
296.36
289.65
mu/l
0.04
11
55
5
7
7.19
2.55
1.0
1.4
1.84
1.83
umol/24h
—
5
7
39
234
1.72
2.49
1.5
1.4
—
—
—
0
0
35
205
1.75
2.43
2.3
1.8
9.17
8.36
u/l
0.10
22
151
20
97
2.10
2.40
1.7
1.4
—
—
—
0
0
456
4253
1.40
2.39
6.5
5.8
38.10
38.56
mmol/mol
0.58
421
4025
8
203
0.39
2.33
1.0
1.1
1.54
1.55
g/l
—
8
203
13
53
2.49
2.29
1.2
1.2
—
—
—
0
0
59
402
1.52
2.28
10.3
7.8
1.24
1.25
mmol/l
0.01
47
306
172
1416
1.31
2.22
5.9
3.9
0.01
0.01
estimate
0.24
69
511
459
4302
1.38
2.20
4.3
4.1
1.29
1.26
mmol/l
0.46
425
4016
484
4578
1.43
2.18
5.8
5.4
2.66
2.75
mmol/l
1.50
451
4297
31
182
1.74
2.16
2.7
4.6
152.82
185.01
%
1.53
31
177
542
5265
2.08
2.14
33.0
22.1
254.65
255.95
e9/l
0.17
531
5148
542
5268
2.06
2.09
32.9
22.1
4.51
4.53
e12/l
0.63
532
5133
73
535
1.42
1.98
5.0
4.5
29.24
31.72
%
1.61
51
359
165
1374
1.28
1.92
1.6
1.4
0.94
1.61
u/ml
1.02
40
357
9
34
2.67
1.87
1.0
3.3
9551.89
761.88
u/ml
—
9
34
11
46
2.42
1.86
1.9
2.5
10.17
15.06
index
—
6
33
13
60
2.19
1.79
1.2
1.6
—
—
—
0
0
6
18
3.36
1.75
2.0
1.2
0.57
0.47
e9/l
—
6
18
135
1109
1.29
1.74
2.0
2.3
1.33
1.27
mg/l
0.07
102
868
475
4516
1.35
1.74
5.2
4.7
1.42
1.46
mmol/l
1.20
445
4238
30
188
1.63
1.69
1.3
1.3
—
—
—
0
0
38
253
1.54
1.68
2.5
2.3
831.13
5152.37
u/l
—
8
103
32
205
1.59
1.66
2.7
6.4
96.97
92.52
%
0.51
32
198
10
210
0.47
1.63
1.1
1.1
0.96
0.89
g/l
—
10
210
443
4188
1.28
1.57
26.4
18.1
13.64
13.50
%
1.33
436
4149
10
45
2.24
1.47
1.1
1.6
—
—
—
0
0
10
45
2.24
1.47
1.1
1.6
—
—
—
0
0
10
45
2.24
1.47
1.1
1.6
—
—
—
0
0
15
80
1.90
1.46
1.1
1.1
4.51
2.94
eliau/ml
—
8
34
10
46
2.19
1.40
1.7
2.7
107.30
106.26
mmol/l
—
10
46
10
46
2.19
1.40
1.7
2.7
1.28
1.19
mmol/l
—
10
46
24
150
1.63
1.40
1.3
1.3
292.82
317.16
ug/g
0.18
13
79
8
163
0.48
1.38
1.5
1.7
—
—
—
0
0
6
24
2.51
1.30
2.8
1.8
—
—
—
0
0
8
34
2.37
1.29
1.0
1.3
—
—
—
0
0
10
48
2.10
1.28
2.0
3.7
1.80
3.22
nmol/l
—
10
48
57
435
1.35
1.26
3.9
3.2
—
—
—
0
0
6
25
2.41
1.24
1.2
1.3
—
—
—
0
0
6
25
2.41
1.24
1.3
1.8
1.33
7.83
u/field
—
6
18
6
25
2.41
1.24
1.2
1.3
—
—
—
0
0
46
609
0.73
1.22
1.8
1.9
3.15
3.49
ratio
1.38
37
471
23
148
1.58
1.22
1.7
1.3
—
—
—
0
0
5
19
2.64
1.22
1.2
1.3
—
—
—
0
0
5
19
2.64
1.22
1.2
1.3
—
—
—
0
0
44
326
1.38
1.18
2.1
1.6
23.32
22.25
iu/l
0.06
31
263
216
1938
1.19
1.17
5.9
3.6
0.02
0.02
estimate
0.12
62
449
8
39
2.07
1.15
1.3
1.7
—
—
—
0
0
8
39
2.07
1.15
1.3
1.6
3.90
5.02
umol/l
—
8
33
5
111
0.45
1.14
2.8
3.2
4.06
11.46
umol/l
—
5
88
10
182
0.54
1.12
1.8
1.6
—
—
—
0
0
17
104
1.65
1.10
1.5
1.8
—
—
—
0
0
5
21
2.39
1.09
2.0
2.6
64.00
89.02
ug/l
—
5
21
8
41
1.96
1.09
2.9
2.4
—
—
—
0
0
11
192
0.56
1.08
1.5
1.5
—
—
—
0
0
13
74
1.77
1.07
1.1
1.1
—
—
—
0
0
43
324
1.35
1.06
1.8
1.6
—
—
—
0
0
7
33
2.13
1.06
2.0
3.1
662.86
628.42
mg
—
7
33
80
657
1.25
1.05
1.9
1.9
1.73
1.48
%
1.17
71
579
73
593
1.27
1.05
4.2
3.9
7.33
7.05
umol/l
0.06
53
523
12
68
1.78
1.01
1.0
1.0
1.56
1.40
g/l
0.75
12
62
13
76
1.73
0.99
1.5
1.3
—
266.67
—
0
6
44
337
1.33
0.99
2.4
2.2
4.99
8.12
ug/l
1.20
38
301
37
488
0.74
0.98
1.9
1.9
—
—
—
0
0
29
207
1.42
0.98
2.7
2.3
33.58
5.70
iu/ml
—
9
49
20
132
1.53
0.98
4.0
2.8
—
—
—
0
0
5
23
2.18
0.98
1.0
1.7
—
—
—
0
0
5
23
2.18
0.98
1.0
1.7
—
—
—
0
0
5
23
2.18
0.98
1.0
1.7
—
—
—
0
0
5
23
2.18
0.98
1.0
1.7
—
—
—
0
0
0
30
0.00
0.97
0.0
1.1
—
—
—
0
0
6
117
0.51
0.95
1.3
1.6
44.66
51.24
ug/l
—
6
117
7
37
1.90
0.94
1.1
1.2
103.00
108.35
pmol/l
—
7
37
218
1996
1.15
0.87
2.1
1.9
1.37
1.36
mmol/l
0.04
189
1720
160
1432
1.16
0.87
5.4
3.2
0.05
0.07
estimate
0.10
62
427
11
64
1.73
0.86
1.2
1.4
0.60
0.52
nmol/l
0.48
11
57
6
31
1.94
0.84
1.0
1.0
—
—
—
0
0
8
45
1.79
0.84
2.8
4.3
105.75
96.53
%
—
8
45
8
140
0.57
0.84
1.5
1.8
—
—
—
0
0
23
163
1.43
0.83
1.5
1.9
—
—
—
0
0
11
65
1.71
0.82
1.0
1.2
—
—
—
0
0
26
189
1.39
0.82
1.3
1.8
—
—
—
0
0
6
32
1.88
0.82
21.3
10.8
0.60
0.62
mmol/l
—
6
32
8
47
1.71
0.81
1.1
1.2
—
98.75
—
0
8
6
33
1.83
0.79
1.7
2.2
0.50
0.82
index
—
6
33
60
720
0.81
0.78
3.5
3.0
0.67
0.75
ug/l
0.44
38
429
15
99
1.53
0.76
5.3
3.5
8.52
7.14
pmol/l
0.30
15
99
5
25
2.01
0.73
1.2
1.2
9.60
10.36
u/l
—
5
25
16
228
0.69
0.71
1.6
1.8
5.77
3.02
mg/l
0.58
11
167
18
126
1.44
0.71
1.7
1.7
—
—
—
0
0
49
401
1.24
0.71
1.1
1.3
134.33
229.29
u/ml
0.55
43
363
5
26
1.93
0.70
2.2
1.5
12.60
13.04
u/l
—
5
26
33
257
1.30
0.70
2.0
1.5
0.44
0.31
mg/l
0.42
11
115
7
41
1.72
0.70
1.0
1.3
—
—
—
0
0
9
58
1.56
0.70
2.3
1.4
—
—
—
0
0
9
58
1.56
0.70
2.3
1.4
—
—
—
0
0
9
59
1.53
0.68
2.3
1.4
—
—
—
0
0
5
27
1.86
0.68
1.2
1.8
5.56
1.35
nmol/l
—
5
21
7
42
1.67
0.68
1.0
1.3
—
—
—
0
0
17
121
1.42
0.63
1.0
1.4
80.88
98.56
pmol/l
0.18
17
116
32
398
0.79
0.60
1.7
1.8
—
—
—
0
0
39
472
0.81
0.58
1.4
1.7
3.21
3.48
mmol/l
0.90
29
337
19
141
1.36
0.57
1.4
1.4
—
—
—
0
0
20
150
1.35
0.56
1.6
2.1
11.73
4.96
iu/l
—
6
63
43
358
1.22
0.56
1.6
1.5
—
—
—
0
0
9
60
1.51
0.54
2.4
1.4
—
—
—
0
0
9
60
1.51
0.54
2.3
1.4
—
—
—
0
0
9
60
1.51
0.54
2.4
1.4
—
—
—
0
0
11
74
1.50
0.53
1.5
1.4
—
—
—
0
0
38
314
1.23
0.53
1.1
1.0
—
—
—
0
0
22
280
0.78
0.51
1.2
1.3
—
—
—
0
0
125
1142
1.12
0.51
3.9
3.2
324.32
335.17
umol/l
0.54
112
1018
18
136
1.33
0.49
1.3
1.6
—
—
—
0
0
11
76
1.46
0.48
1.7
1.7
—
—
—
0
0
14
102
1.38
0.47
1.1
1.1
1.00
39.92
iu/ml
—
5
25
14
102
1.38
0.47
1.8
1.3
—
—
—
0
0
16
120
1.34
0.46
1.3
1.3
—
—
—
0
0
11
77
1.44
0.45
1.2
1.8
—
—
—
0
0
43
368
1.18
0.44
3.0
2.7
0.13
0.46
e6/l
0.72
43
348
13
95
1.38
0.44
2.2
1.3
—
—
—
0
0
21
166
1.27
0.44
1.6
1.4
—
—
—
0
0
8
56
1.43
0.42
1.3
1.4
—
—
—
0
0
16
206
0.77
0.42
1.5
1.7
—
—
—
0
0
0
17
0.00
0.40
0.0
2.6
—
10.62
—
0
17
0
17
0.00
0.40
0.0
2.6
—
4.64
—
0
17
360
3493
1.09
0.40
3.2
3.4
—
—
—
0
0
5
35
1.43
0.39
1.6
1.7
—
—
—
0
0
10
72
1.40
0.37
1.1
1.2
111.70
116.18
%
—
10
65
75
822
0.90
0.35
2.5
2.1
—
—
—
0
0
21
172
1.23
0.34
1.1
1.2
0.99
2.88
u/ml
1.20
13
111
6
44
1.37
0.34
4.7
3.3
18.00
55.92
u/ml
—
6
44
6
46
1.31
0.33
1.0
1.2
—
—
—
0
0
6
47
1.28
0.32
1.0
1.2
—
—
—
0
0
6
47
1.28
0.32
1.7
1.8
—
—
—
0
0
6
47
1.28
0.32
1.0
1.2
—
—
—
0
0
7
52
1.35
0.31
1.0
1.2
—
—
—
0
0
14
111
1.27
0.30
1.2
1.7
—
—
—
0
0
13
102
1.28
0.30
1.4
1.6
—
—
—
0
0
19
157
1.22
0.30
1.5
1.8
—
—
—
0
0
51
459
1.12
0.29
2.3
2.4
29.88
33.76
u/l
0.54
43
383
7
56
1.25
0.29
1.1
1.1
84.14
98.38
%
—
7
50
88
944
0.92
0.28
4.4
4.3
22.16
21.76
%
0.07
32
422
101
946
1.08
0.27
1.2
1.3
10.13
29.47
iu/ml
5.78
22
279
9
118
0.76
0.27
2.2
1.4
—
—
—
0
0
41
366
1.13
0.27
2.4
2.8
78.00
69.98
ml/min/173m2
0.49
18
156
49
443
1.12
0.27
2.9
2.5
11.18
12.91
nmol/l
0.76
44
411
15
122
1.24
0.27
1.6
1.8
—
—
—
0
0
10
77
1.30
0.26
1.3
1.3
5.40
4.63
u/ml
—
5
35
18
151
1.20
0.25
1.2
1.1
4.54
1.56
u/ml
0.32
12
91
21
180
1.17
0.24
1.3
1.3
—
—
—
0
0
120
1139
1.07
0.24
5.7
3.9
1.02
1.02
kg/l
0.08
82
758
7
91
0.77
0.22
2.1
1.5
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
5
41
1.22
0.22
1.2
1.4
—
—
—
0
0
5
41
1.22
0.22
26.2
14.3
789.40
801.17
nmol/l
—
5
41
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
2.72
—
0
5
0
11
0.00
0.21
0.0
1.2
—
72.45
—
0
11
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
0.09
—
0
13
7
59
1.19
0.18
1.0
1.2
—
—
—
0
0
72
757
0.94
0.15
2.4
2.0
—
—
—
0
0
7
88
0.79
0.14
1.4
1.4
2.55
3.20
ug/l
—
7
77
11
94
1.17
0.13
1.8
3.9
25.00
25.29
mg/l
—
5
67
126
1227
1.03
0.10
1.8
1.8
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
13
145
0.89
0.09
1.2
1.2
—
—
—
0
0
5
47
1.06
0.09
1.0
1.1
—
—
—
0
0
122
1191
1.03
0.09
5.0
5.0
1.54
2.31
ug/l
1.60
112
1072
6
57
1.05
0.08
2.0
1.6
—
—
—
0
0
6
58
1.03
0.08
1.0
1.0
—
—
—
0
0
16
146
1.10
0.08
1.3
1.7
239.00
199.08
u/ml
—
7
79
6
75
0.80
0.07
1.2
1.3
—
—
—
0
0
7
85
0.82
0.07
2.3
1.7
—
—
—
0
0
84
860
0.97
0.06
1.3
1.3
1.29
8.23
u/ml
4.07
26
349
22
207
1.06
0.06
1.3
1.3
325.15
260.62
miu/ml
0.29
11
101
18
191
0.94
0.05
2.0
1.6
20.23
7.73
u/ml
—
8
39
17
178
0.95
0.02
2.1
2.0
47.41
37.62
nmol/l
0.79
17
169
84
831
1.01
0.01
1.5
1.5
—
—
—
0
0
14
146
0.96
0.00
1.1
1.2
—
—
—
0
0
39
396
0.98
0.00
4.6
4.4
3.94
18.27
ug/l
0.73
28
324
41
411
1.00
0.00
1.1
1.3
123.85
134.30
u/ml
0.06
13
171
14
136
1.03
0.00
1.9
2.0
171.29
226.59
pmol/l
1.46
14
128
10
100
1.00
0.00
2.0
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
2.1
—
3.99
—
0
7
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
6.10
—
0
5
5
58
0.86
-0.00
1.0
1.1
2.53
1.45
nmol/l
—
5
53
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_NYSTAGMUS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_NYSTAGMUS | 1.772 [1.39, 2.25] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.166 |
During the follow-up period (1.1.1998 — 31.12.2019), 175 out of 1946 females with H7_NYSTAGMUS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_NYSTAGMUS | 2.021 [1.62, 2.52] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 210 out of 2046 males with H7_NYSTAGMUS died.
Mortality risk
Mortality risk for people of age
years, who have H7_NYSTAGMUS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.126% | 0.334% |
| 5 | 1.05% | 2.326% |
| 10 | 2.605% | 5.471% |
| 15 | 4.768% | 10.192% |
| 20 | 8.138% | 17.425% |
Relationships between endpoints
↥Index endpoint: H7_NYSTAGMUS – Nystagmus and other irregular eye movements
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data